Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 67, Issue 2, 2007, Pages 548-554

  Siissalo, Sanna ^a   Laitinen, Leena ^a   Koljonen, Maija ^a   Vellonen, Kati Sisko ^a   Kortejärvi, Hanna ^b   Urtti, Arto ^a   Hirvonen, Jouni ^a   Kaukonen, Ann Marie ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Caco 2 cell line; Cell differentiation; Efflux protein; Expression; Functionality; MDR1; Passage number

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; RHODAMINE 123; VERAPAMIL; VINBLASTINE;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN CACO 2; CONTROLLED STUDY; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CACO-2 CELLS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; GENE EXPRESSION REGULATION; HUMANS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINE 123; RNA, MESSENGER; TECHNOLOGY, PHARMACEUTICAL; VINBLASTINE;

EID: 34547663275     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.03.017     Document Type: Article

References (33)

1. Ayrton A., and Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31 (2001) 469-497
2. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., and Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38 (1990) 1277-1287
3. Takano M., Yumoto R., and Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109 (2006) 137-161
4. Pinto M., Robine-Leon S., Appay M., Kedinger M., Triadou N., Dussaulx E., Lacroix B., Simon-Assmann P., Haffen K., Fogh J., and Zweibaum A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47 (1983) 323-330
5. Hilgers A.R., Conradi R.A., and Burton P.S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7 (1990) 902-910
6. Gan L.L., and Thakker D.R. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug Deliv. Rev. 23 (1997) 77-98
7. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., and Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal epithelial Caco-2 cells. J. Biol. Chem. 268 (1993) 14991-14997
8. Anderle P., Niederle E., Rubas W., Hilgendorf C., Spahn-Langguth H., Wunderli-Allenspach H., Merkle H.P., and Langguth P. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 87 (1998) 757-762
9. Hosoya K., Kim K., and Lee V.H.L. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13 (1996) 885-890
10. Döppenschmitt S., Langguth P., Regårdh C.G., Andersson T.B., Hilgendorf C., and Spahn-Langguth H. Characterization of binding properties to human P-glycoprotein: Development of a [3H]verapamil radioligand-binding assay. J. Pharmacol. Exp. Ther. 288 (1999) 348-357
11. Eneroth A., Astrom E., Hoogstraate J., Schrenk D., Conrad S., Kauffmann H.M., and Gjellan K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci. 12 (2001) 205-214
12. Laska D.A., Houchins J.O., Pratt S.E., Horn J., Xia X., Hanssen B.R., Williams D.C., Dantzig A.H., and Lindstrom T. Characterization and application of a vinblastine-selected Caco-2 cell line for evaluation of P-glycoprotein. In Vitro Cell Dev. Biol. Anim. 38 (2002) 401-410
13. Prime-Chapman H.M., Fearn R.A., Cooper A.E., Moore V., and Hirst B.H. Differential MRP1-6 isoform expression and function in human intestinal epithelial Caco-2 cells. J. Pharm. Exp. Ther. 311 (2004) 476-484
14. Hirohashi T., Suzuki H., Chu X.Y., Tamai I., Tsuji A., and Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J. Pharm. Exp. Ther. 292 (2000) 265-270
15. Horie K., Tang F., and Borchardt R.T. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm. Res. 20 (2003) 161-168
16. Hunter J., and Hirst B.J. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Del. Rev. 25 (1997) 129-157
17. Salphati L., and Benet L.Z. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem. Pharmacol. 55 (1998) 387-395
18. Li Q., Sai Y., Kato Y., Tamai I., and Tsuji A. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm. Res. 20 (2003) 1119-1124
19. Korjamo T., Honkakoski P., Toppinen M.-R., Niva S., Reinisalo M., Palmgren J.J., and Monkkonen J. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur. J. Pharm. Sci. 26 (2005) 266-279
20. Koljonen M., Hakala K.S., Ahtola-Satila T., Laitinen L., Kostiainen R., Kotiaho T., Kaukonen A.M., and Hirvonen J. Evaluation of cocktail approach to standardise Caco-2 permeability experiments. Eur. J. Pharm. Biopharm. 64 (2006) 379-387
21. Barrand M.A., Rhodes T., Center M.S., and Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833, and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer 29 (1993) 408-415
22. Honda Y., Ushigome F., Koyabu N., Morimoto S., Shoyama Y., Uchiumi T., Kuwano M., Ohtani H., and Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. Pharmacol. 143 (2004) 856-864
23. Zhang Y., Gupta A., Wang H., Zhou L., Vethanayagam R.R., Unadkat J.D., and Mao Q. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22 (2005) 2023-2034
24. Alsenz J., and Haenel E. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm. Res. 20 (2003) 1961-1969
25. Yamashita S., Konishi K., Yamazaki Y., Taki Y., Sakane T., Sezaki H., and Furuyama Y. New and better protocols for a short-term Caco-2 cell culture system. J. Pharm. Sci. 91 (2002) 669-679
26. Miret S., Abrahamse L., and de Groene E.M. Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J. Biomol. Screen. 9 (2004) 598-606
27. Shirasaka Y., Kawasaki M., Sakane T., Omatsu H., Moriya Y., Nakamura T., Sakaeda T., Okumura K., Langguth P., and Yamashita S. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab. Pharmacokinet. 21 (2006) 414-423
28. Briske-Anderson M.J., Finley J.W., and Newman S.M. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc. Soc. Exp. Biol. Med. 214 (1997) 248-257
29. Wandel C., Kim R.B., Kajiji S., Guengerich P., Wilkinson G.R., and Wood A.J. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59 (1999) 3944-3948
30. Gutmann H., Fricker G., Török M., Michael S., Beglinger C., and Drewe J. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm. Res. 16 (1999) 402-407
31. Ito K., Suzuki H., Horie T., and Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22 (2005) 1559-1577
32. Taipaleensuu J., Tavelin S., Lazorova L., Svensson A.-C., and Artursson P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function as a marker of MDR1-dependent drug efflux activity. Eur. J. Pharm. Sci. 21 (2004) 69-75
33. Cummins C.L., Mangravite L.M., and Benet L.Z. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1 and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm. Res. 18 (2001) 1102-1109